Skip to content
GERICLINICS

GeriQBank · Paper II · Q8

COVID-19 in the older adult — presentation and management

Not rated7-mark answer
Chapter
Part III — Viral and Vaccine-Preventable Infection
Years asked
Not recorded in the source
Frequency
No university frequency data for this paper yet

Detailed answer

Pro · free in beta
Attempt it firstOutline your answer as a 7-mark answer before revealing it — definition, causes, evaluation, management and the geriatric angle.Reveal answer

ANSWER

Textbook Core — 6 Points

1.

Why older adults are the highest-risk group. Immunosenescence and inflammaging, multimorbidity, reduced pulmonary and cardiac reserve, and frailty make age the single strongest predictor of severe disease and death. Residents of long-term care facilities are at particular risk because of close cohabitation and shared staff. The great majority of COVID-19 hospitalisations occur in those ≥65 years, with the highest rates over 75.

2.

Atypical presentation. Delirium or acute confusion may be the sole presenting feature. Also falls, functional decline, anorexia, generalised weakness, unexplained tachypnoea and "silent hypoxia" — significant desaturation without breathlessness. Fever may be absent because of the blunted febrile response of ageing; anosmia is reported less often than in younger patients.

3.

Assessment. Pulse oximetry is essential (target SpO 94–98%, or 88–92% if at risk of hypercapnia); respiratory rate; 2 CBC (lymphopenia), CRP, renal and liver function, blood glucose, D-dimer, ECG and chest imaging; RT-PCR or rapid antigen test. Document a Clinical Frailty Scale score and comorbidity — used alongside, never instead of, clinical assessment when making escalation decisions. Screen for delirium with the 4AT.

4.

Mild-to-moderate disease in a high-risk older adult. Start an antiviral within 5 days of symptom onset. Nirmatrelvir/ritonavir is first line — dose-reduce if eGFR 30–60 mL/min, avoid if eGFR <30, and check for CYP3A4 interactions, which are the major geriatric pitfall (statins, calcium-channel blockers, amiodarone, DOACs, tacrolimus, some antipsychotics — many need temporary suspension or dose reduction). Alternatives: remdesivir (3-day IV course) or molnupiravir.

5.

Severe disease (hypoxia). Controlled oxygen, awake proning if tolerated, dexamethasone 6 mg daily for up to 10 days (only if hypoxic), plus tocilizumab or baricitinib in rapidly progressive inflammatory disease; escalate to HFNO/NIV/ventilation according to agreed goals of care. Give LMWH thromboprophylaxis unless contraindicated. Antibiotics only when bacterial co-infection is genuinely suspected. Monitor for hyperglycaemia and steroid-induced delirium.

6.

The geriatric care bundle. Delirium prevention (reorientation, hearing aids and spectacles, hydration, early mobilisation, sleep hygiene, minimising sedatives and restraints); nutrition and swallow assessment; pressure-ulcer prevention; medication review; early rehabilitation for deconditioning and post-COVID functional decline; and explicit advance care planning and goals-of-care discussion with the patient and family. Prevention: updated COVID-19, influenza and pneumococcal vaccination, ventilation, and IPC in long-term care.

Latest Update (2023 – present)

7.

The 2025 IDSA guideline update continues to strongly recommend nirmatrelvir/ritonavir for high-risk adults with mild-to-moderate COVID-19. However, the PANORAMIC and CanTreatCOVID platform trials (NEJM 2026), conducted in a largely vaccinated higher-risk community population, found faster symptom recovery but no significant reduction in hospitalisation or death — so the absolute benefit is now understood to be greatest in the unvaccinated, immunocompromised and oldest-old. CDC 2025–2026 guidance recommends COVID-19 vaccination for adults ≥65 years through individual-based (shared clinical) decision-making, and CDC MMWR 2026 data show only about 31% of eligible outpatients ≥65 years receive an antiviral within 7 days — under-treatment, not over-treatment, is the current practice gap. If this appears as a 15-mark question, add: pathophysiology (ACE2, cytokine response, endothelial injury, immunothrombosis); a severity classification table (mild / moderate / severe / critical with SpO and respiratory rate cut-offs); 2 the Indian Ministry of Health clinical management protocol and its home-isolation criteria; specific management of long COVID / post-COVID syndrome in older adults (fatigue, breathlessness, cognitive impairment, deconditioning, and the role of pulmonary rehabilitation); the ethical framework for triage and ceilings of care in frail older adults; and lessons for outbreak management in Indian old-age homes.

Exam One-Liners

Commonest atypical presentation — delirium.

Most dangerous missed sign — silent hypoxia.

Antiviral window — within 5 days.

Biggest practical problem with nirmatrelvir/ritonavir — CYP3A4 drug interactions. Steroids — only if hypoxic; dexamethasone 6 mg × up to 10 days.

Frailty score — used with, not instead of, clinical judgement.

How was your recall?

Rating marks the question complete. “Need another pass” also adds it to your bookmarks.

References

Spotted an error or something out of date?Report a problem with this page